Tenax ends Phase 3 TNX-103 trial with non-significant primary results

Tenax Therapeutics reports that its Phase 3 LEVEL study for TNX-103 did not meet its primary endpoint, though exploratory analysis showed reduced NT-proBNP and improved walk distances in patients with higher disease burden.